Pharming Group (OTCMKTS:PHGUF) Reaches New 1-Year High – Should You Buy?

Pharming Group NV (OTCMKTS:PHGUF)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $2.17 and last traded at $2.17, with a volume of 5490 shares changing hands. The stock had previously closed at $1.65.

Pharming Group Price Performance

The firm has a market capitalization of $1.24 billion, a P/E ratio of 215.22 and a beta of 0.37. The stock’s 50 day simple moving average is $1.67 and its 200 day simple moving average is $1.47. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.39 and a current ratio of 3.16.

Pharming Group (OTCMKTS:PHGUF) last released its quarterly earnings data on Thursday, November 6th. The biotechnology company reported $0.01 EPS for the quarter. Pharming Group had a return on equity of 0.46% and a net margin of 0.30%.The company had revenue of $97.30 million for the quarter, compared to the consensus estimate of $80.18 million.

About Pharming Group

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.